Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.38 |
| ▸ | AKT2 | P31751 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | HAT1 | O14929 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17950152 | 0.81 | MEN1 (0.46) | NAMPTAKT2ROCK2NOS2HRH2 | |
| SCHEMBL22212352 | 0.81 | AKT2 (0.41) | NAMPTAKT2ROCK2NOS2HRH2 | |
| SCHEMBL24866428 | 0.79 | AKT2 (0.44) | NAMPTAKT2NOS2HRH2KCNH2 | |
| SCHEMBL19001245 | 0.78 | HRH4 (0.42) | NAMPTAKT2NOS2PDCD1LG2CD274 | |
| SCHEMBL21099036 | 0.77 | HRH4 (0.44) | NAMPTAKT2ROCK2NOS2HRH2 | |
| SCHEMBL21263656 | 0.76 | NOS2 (0.44) | AKT2NOS2HAT1EP300KCNH2 | |
| SCHEMBL11588923 | 0.74 | — | — | |
| SCHEMBL836016 | 0.74 | — | — | |
| SCHEMBL292535 | 0.74 | — | — | |
| SCHEMBL32670416 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208032-B2 | Benzamide and nicotinamide compounds and methods of using same | ONCOTARTIS INC. (US) | 2019-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208032-B2 | Benzamide and nicotinamide compounds and methods of using same | NAMPT, NNT, NADK | NAMPT 1/4885AKT2 1555/4885ROCK2 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.